KR102194644B1 - 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 - Google Patents

신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 Download PDF

Info

Publication number
KR102194644B1
KR102194644B1 KR1020190049295A KR20190049295A KR102194644B1 KR 102194644 B1 KR102194644 B1 KR 102194644B1 KR 1020190049295 A KR1020190049295 A KR 1020190049295A KR 20190049295 A KR20190049295 A KR 20190049295A KR 102194644 B1 KR102194644 B1 KR 102194644B1
Authority
KR
South Korea
Prior art keywords
leu
ser
thr
val
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020190049295A
Other languages
English (en)
Korean (ko)
Other versions
KR20190124665A (ko
Inventor
김정호
김범석
Original Assignee
주식회사 굳티셀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 굳티셀 filed Critical 주식회사 굳티셀
Publication of KR20190124665A publication Critical patent/KR20190124665A/ko
Application granted granted Critical
Publication of KR102194644B1 publication Critical patent/KR102194644B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020190049295A 2018-04-26 2019-04-26 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 Active KR102194644B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180048343 2018-04-26
KR20180048343 2018-04-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020200177336A Division KR20200144524A (ko) 2018-04-26 2020-12-17 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물

Publications (2)

Publication Number Publication Date
KR20190124665A KR20190124665A (ko) 2019-11-05
KR102194644B1 true KR102194644B1 (ko) 2020-12-24

Family

ID=68293649

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020190049295A Active KR102194644B1 (ko) 2018-04-26 2019-04-26 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
KR1020200177336A Ceased KR20200144524A (ko) 2018-04-26 2020-12-17 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
KR1020230131463A Active KR102754984B1 (ko) 2018-04-26 2023-10-04 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020200177336A Ceased KR20200144524A (ko) 2018-04-26 2020-12-17 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
KR1020230131463A Active KR102754984B1 (ko) 2018-04-26 2023-10-04 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물

Country Status (6)

Country Link
US (1) US11820801B2 (https=)
EP (1) EP3792276A4 (https=)
JP (1) JP7485368B2 (https=)
KR (3) KR102194644B1 (https=)
CN (1) CN112041333B (https=)
WO (1) WO2019209078A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210347849A1 (en) * 2018-07-24 2021-11-11 Good T Cells, Inc. Composition for Preventing or Treating Immune-Related Diseases
CN113811330A (zh) * 2019-03-20 2021-12-17 古德T细胞有限公司 预防或治疗脑和神经系统疾病的组合物
AU2020380072B2 (en) * 2019-11-08 2025-11-27 Good T Cells, Inc. Epitope of regulatory T cell surface antigen, and antibody specifically binding thereto
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用
KR20250036703A (ko) * 2023-09-06 2025-03-14 주식회사 굳티셀 친화도 성숙이 이루어진 신규 항체

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
US20110151433A1 (en) 2005-09-27 2011-06-23 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
WO2013184939A2 (en) 2012-06-08 2013-12-12 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
US20150010556A1 (en) 2012-10-04 2015-01-08 Research Development Foundation Serine protease molecules and therapies
US20150239964A1 (en) * 2011-01-24 2015-08-27 Sang-Kyou Lee Novel Use of Regulatory T Cell-Specific Surface Protein LRIG-1

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
JP2008504008A (ja) * 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
WO2007013671A2 (en) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
CN105131127B (zh) 2007-05-30 2018-09-07 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
US8933197B2 (en) * 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
CN101891823B (zh) * 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
WO2015016616A1 (ko) * 2013-07-30 2015-02-05 연세대학교 산학협력단 삭사틸린-Ｆｃ 융합 단백질 및 이의 용도
US20210347849A1 (en) 2018-07-24 2021-11-11 Good T Cells, Inc. Composition for Preventing or Treating Immune-Related Diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110151433A1 (en) 2005-09-27 2011-06-23 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
US20150239964A1 (en) * 2011-01-24 2015-08-27 Sang-Kyou Lee Novel Use of Regulatory T Cell-Specific Surface Protein LRIG-1
KR101847523B1 (ko) 2011-01-24 2018-05-28 연세대학교 산학협력단 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
WO2013184939A2 (en) 2012-06-08 2013-12-12 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
US20150010556A1 (en) 2012-10-04 2015-01-08 Research Development Foundation Serine protease molecules and therapies

Also Published As

Publication number Publication date
EP3792276A4 (en) 2022-02-16
KR20230146491A (ko) 2023-10-19
US20210130422A1 (en) 2021-05-06
JP2021521817A (ja) 2021-08-30
US11820801B2 (en) 2023-11-21
KR102754984B1 (ko) 2025-01-21
JP7485368B2 (ja) 2024-05-16
CN112041333B (zh) 2024-06-28
CN112041333A (zh) 2020-12-04
KR20200144524A (ko) 2020-12-29
WO2019209078A1 (ko) 2019-10-31
KR20190124665A (ko) 2019-11-05
EP3792276A1 (en) 2021-03-17

Similar Documents

Publication Publication Date Title
KR102754984B1 (ko) 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
KR102714455B1 (ko) 이중특이성 재조합단백질 및 이의 응용
CN109575140B (zh) 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
AU2017202437B2 (en) Novel immunoconjugates
DK3075745T3 (en) Mutated interleukin-2 polypeptides
KR102263643B1 (ko) 면역 관련 질환의 예방 또는 치료용 조성물
CN107835820B (zh) 识别癌症特异性IL13Rα2的CAR T细胞
CA3087423A1 (en) Anti-claudin 18.2 antibodies
KR20230041819A (ko) Hla-g 항원-결합 도메인을 포함하는 단백질 및 이의 용도
TW200823235A (en) Prophylactic and therapeutic agent for cancers
KR20230059789A (ko) 항-가변 muc1* 항체 및 이의 용도
KR20230137393A (ko) Psma 결합 단백질 및 이의 용도
CN110028584A (zh) 针对egfr蛋白和met蛋白的双特异性抗体
CN111051350A (zh) 包含信号调节蛋白α的免疫缀合物
CN112794911A (zh) 人源化抗叶酸受体1抗体及其应用
KR20220031054A (ko) Egfrviii에 결합하는 단일클론 항체 및 이의 용도
JP2021521817A5 (https=)
KR20230165829A (ko) 이중특이적 분자 및 관련 조성물 및 방법
CN112409484B (zh) 多功能抗体、其制备及其用途
JPWO2019209078A5 (https=)
KR20210017449A (ko) 신규한 융합 단백질 및 이의 용도
CN118307671A (zh) Pd-1结合分子及其用途
KR20230164118A (ko) 암 치료를 위한 치료 조합
CN117186222A (zh) Pd-l1结合分子及其用途
KR20220088438A (ko) 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20190426

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200722

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20201127

A107 Divisional application of patent
GRNT Written decision to grant
PA0107 Divisional application

Comment text: Divisional Application of Patent

Patent event date: 20201217

Patent event code: PA01071R01D

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20201217

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20201218

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20231109

Start annual number: 4

End annual number: 4